Authors: John A Kanis Rene Rizzoli Cyrus Cooper JeanYves Reginster
Publish Date: 2014/04/01
Volume: 94, Issue: 5, Pages: 469-473
Abstract
JAK has received consulting fees advisory board fees lecture fees and/or grant support from the majority of companies concerned with skeletal metabolism C C has received consulting fees and paid advisory boards for Alliance for Better Bone Health GlaxoSmithKline Roche Merck Sharp and Dohme Lilly Amgen Wyeth Novartis Servier and Nycomed RR Paid advisory boards and lecture fee for Merck Sharp and Dohme Eli Lilly Amgen Servier Takeda and Danone JY R on behalf of the Department of Public Health Epidemiology and Health Economics of the University of Liège Liège Belgium Consulting fees or paid advisory boards Servier Novartis Negma Lilly Wyeth Amgen GlaxoSmithKline Roche Merckle Nycomed NPS Theramex UCB Lecture fees when speaking at the invitation of a commercial sponsor Merck Sharp and Dohme Lilly Rottapharm IBSA Genevrier Novartis Servier Roche GlaxoSmithKline Teijin Teva Ebewee Pharma Zodiac Analis Theramex Nycomed NovoNordiskThe authors consulted Amgen Andreas Grauer Asahi Kasei Pharma Koshi Sakamoto Yasuo Nakamura Masaya Etoh Servier Florence Petit Dop Yannis Tsouderos and UCB John Caminis to discuss problems in the development of boneforming agents The consultees had no part in the writing of this report
Keywords: